New cancer drug enters human testing for multiple advanced tumors

NCT ID NCT06238479

Recruiting now Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

Summary

This is the first human study of an experimental cancer drug called LY4101174. Researchers want to find a safe dose and see if it can help control advanced cancers that have spread or returned after other treatments. The study will enroll about 490 people with various solid tumors including bladder, breast, lung, and ovarian cancers.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

AdventHealth Orlando
RECRUITING

Orlando, Florida, 32804, United States
Austin Health
RECRUITING

Heidelberg, 3084, Australia
CHU Strasbourg-Hautepierre
RECRUITING

Strasbourg, 67098, France
Centre Leon Berard
RECRUITING

Lyon, 69373, France
Centre Oscar Lambret
RECRUITING

Lille, 59020, France
Emory University
RECRUITING

Atlanta, Georgia, 30322, United States
Gustave Roussy
RECRUITING

Villejuif, 94805, France
Hospital Universitari Vall d'Hebron
RECRUITING

Barcelona, 08035, Spain
Hospital Universitario 12 de Octubre
RECRUITING

Madrid, 28041, Spain
Hospital Universitario Virgen Del Rocio
RECRUITING

Seville, 41013, Spain
Hunan Cancer Hospital
NOT_YET_RECRUITING

Changsha, 410013, China
Icon Cancer Centre Kurralta Park
RECRUITING

Kurralta Park, 5037, Australia
Institut Jules Bordet
RECRUITING

Anderlecht, 1070, Belgium
Institut Paoli-Calmettes
RECRUITING

Marseille, 13273, France
Kyoto University Hospital
RECRUITING

Kyoto, 606-8507, Japan
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
RECRUITING

New York, New York, 10016, United States
MD Anderson Cancer Center
RECRUITING

Madrid, 28033, Spain
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
National Cancer Center Hospital
RECRUITING

Chūōku, 104-0045, Japan
National Cancer Center Hospital East
RECRUITING

Kashiwa, 277-8577, Japan
Peking University First Hospital
RECRUITING

Beijing, 100034, China
Perlmutter Cancer Center at NYU Langone Hospital - Long Island
NOT_YET_RECRUITING

Mineola, New York, 11501, United States
Shanghai East Hospital
NOT_YET_RECRUITING

Shanghai, 200433, China
South Texas Accelerated Research Therapeutics (START)
RECRUITING

San Antonio, Texas, 78229-3307, United States
The Cancer Institute Hospital of JFCR
RECRUITING

Kōtō City, 135-8550, Japan
UT Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390-8884, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMOR BLADDER CANCER CERVICAL CANCER ESOPHAGEAL CANCER HEAD AND NECK SQUAMOUS CELL CARCINOMA METASTATIC SOLID TUMOR NON SMALL CELL LUNG CANCER OVARIAN CANCER PANCREATIC CANCER PROSTATE CANCER RECURRENT SOLID TUMOR RENAL PELVIS CANCER TRIPLE NEGATIVE BREAST CANCER URINARY BLADDER NEOPLASM